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Summary
Background Gastroprotectant drugs are used for the prevention and treatment of peptic ulcer disease and might 
reduce its associated complications, but reliable estimates of the effects of gastroprotectants in different clinical 
settings are scarce. We aimed to examine the effects of proton-pump inhibitors (PPIs), prostaglandin analogues, and 
histamine-2 receptor antagonists (H2RAs) in different clinical circumstances by doing meta-analyses of tabular data 
from all relevant unconfounded randomised trials of gastroprotectant drugs.
Methods We searched MEDLINE and Embase from Jan 1, 1950, to Dec 31, 2015, to identify unconfounded, randomised 
trials of a gastroprotectant drug (defined as a PPI, prostaglandin analogue, or H2RA) versus control, or versus another 
gastroprotectant. Two independent researchers reviewed the search results and extracted the prespecified outcomes 
and key characteristics for each trial. We did meta-analyses of the effects of gastroprotectant drugs on ulcer 
development, bleeding, and mortality overall, according to the class of gastroprotectant, and according to the 
individual drug within a gastroprotectant class.
Findings We identified comparisons of gastroprotectant versus control in 849 trials (142 485 participants): 
580 prevention trials (110 626 participants), 233 healing trials (24 033 participants), and 36 trials for the treatment of 
acute upper gastrointestinal bleeding (7826 participants). Comparisons of one gastroprotectant drug versus another 
were available in 345 trials (64 905 participants), comprising 160 prevention trials (32 959 participants), 167 healing 
trials (28 306 participants), and 18 trials for treatment of acute upper gastrointestinal bleeding (3640 participants). 
The median number of patients in each trial was 78 (IQR 44·0–210·5) and the median duration was 1·4 months 
(0·9–2·8). In prevention trials, gastroprotectant drugs reduced development of endoscopic ulcers (odds ratio 
[OR] 0·27, 95% CI 0·25–0·29; p<0·0001), symptomatic ulcers (0·25, 0·22–0·29; p<0·0001), and upper 
gastrointestinal bleeding (0·40, 0·32–0·50; p<0·0001), but did not significantly reduce mortality (0·85, 0·69–1·04; 
p=0·11). Larger proportional reductions in upper gastrointestinal bleeding were observed for PPIs than for other 
gastroprotectant drugs (PPIs 0·21, 99% CI 0·12–0·36; prostaglandin analogues 0·63, 0·35–1·12; H2RAs 0·49, 
0·30–0·80; phet=0·0005). Gastroprotectant drugs were effective in preventing bleeding irrespective of the use of 
non-steroidal anti-inflammatory drugs (phet=0·56). In healing trials, gastroprotectants increased endoscopic ulcer 
healing (3·49, 95% CI 3·28–3·72; p<0·0001), with PPIs more effective (5·22, 99% CI 4·00–6·80) than prostaglandin 
analogues (2·27, 1·91–2·70) and H2RAs (3·80, 3·44–4·20; phet<0·0001). In trials among patients with acute 
bleeding, gastroprotectants reduced further bleeding (OR 0·68, 95% CI 0·60–0·78; p<0·0001), blood transfusion 
(0·75, 0·65–0·88; p=0·0003), further endoscopic intervention (0·56, 0·45–0·70; p<0·0001), and surgery (0·72, 
0·61–0·84; p<0·0001), but did not significantly reduce mortality (OR 0·90, 0·72–1·11; p=0·31). PPIs had larger 
protective effects than did H2RAs for further bleeding (phet=0·0107) and blood transfusion (phet=0·0130).
Interpretation Gastroprotectants, in particular PPIs, reduce the risk of peptic ulcer disease and its complications and 
promote healing of peptic ulcers in a wide range of clinical circumstances. However, this meta-analysis might have 
overestimated the benefits owing to small study bias.
Funding UK Medical Research Council and the British Heart Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Worldwide, peptic ulcer disease is responsible for 
substantial premature mortality, with much of the 
burden in low-income and middle-income countries.1,2 
Peptic ulcer disease comprises both gastric and duodenal 
ulcers—defects that penetrate, respectively, beyond the 
muscularis mucosae of the gastric or duodenal 
mucosa—and its complications can include upper 
gastrointestinal bleeding, perforation and, rarely, gastric 
outlet obstruction.3,4 Gastroprotectant drugs, defined 
here as proton-pump inhibitors (PPIs), prostaglandin 
analogues, and histamine-2 receptor antagonists 
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(H2RAs), have been developed for the protection of the 
mucosa, healing of mucosal damage, and stabilisation of 
gastrointestinal bleeding, and are prescribed for the 
prevention of peptic ulcer disease, to promote healing, 
and as treatment for bleeding complications.
The most frequent causes of peptic ulcer disease are 
Helicobacter pylori infection and the use of non-steroidal 
anti-inflammatory drugs (NSAIDs), including aspirin.3 
NSAIDs are among the most widely used drugs in the 
world and are known to substantially increase the risk 
of upper gastrointestinal complications5 (probably as a 
consequence of inhibited mucosal prostaglandin prod-
uction). Optimal use of gastroprotectant drugs might 
therefore help to reduce the global burden of peptic 
ulcer disease and its complications. Clinical guidelines 
currently recommend that PPIs are used as first-choice 
gastroprotectant drugs, supported by systematic reviews 
and meta-analyses in particular clinical settings,6–8 but 
to date no comprehensive effort has been made to bring 
together all of the evidence from randomised trials of 
gastroprotectant drugs in different clinical contexts. 
In particular, reliable estimates of the effects of different 
gastroprotectant drugs in specific clinical circumstances 
(eg, in the context of prevention, healing, or acute 
bleeding), at different anatomical locations (gastric or 
duodenal), and according to concomitant NSAID use 
are not available.
We aimed to examine the effects of PPIs, prostaglandin 
analogues, and H2RAs in different clinical circum-
stances by doing meta-analyses of tabular data from all 
relevant unconfounded randomised trials of gastro-
protectant drugs. Here we describe the main findings 
of these analyses.
Methods
Search strategy and selection criteria
Full details of the search strategy, including search 
terms used, are provided in the appendix (pp 34–36). 
We searched MEDLINE and Embase using Ovid SP and 
the Cochrane strategy9 from Jan 1, 1950, to Dec 31, 2015, 
inclusive, with no language restrictions. Studies were 
eligible if they were prospective clinical trials with 
adequate randomisation (ie, randomised sequence 
generation with robust allocation concealment) and 
were unconfounded (ie, protocol-mandated use of 
non-gastroprotectant drugs did not differ between 
treatment groups). We excluded trials if they were 
conducted exclusively among participants with 
non-peptic upper gastrointestinal bleeding (eg, from 
varices), were of less than 2 weeks’ treatment duration 
(except in acute trials of upper gastrointestinal bleeding, 
in which there were no duration constraints), were 
done in a critical care setting, or if treatment was given 
less frequently than once daily. The review of search 
results was done independently by two authors (two of 
HH, KD, KW, and LH).
We included trials if they randomly assigned participants 
to at least one gastroprotectant drug—defined as a PPI, 
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Research in context
Evidence before the study
We searched MEDLINE and Embase from Jan 1, 1950, to 
Dec 31, 2015, for randomised controlled trials of 
gastroprotectant drugs (including proton-pump inhibitors 
[PPIs], histamine-2 receptor antagonists, and prostaglandin 
analogues), with no language restrictions. These searches 
revealed a very large number of studies that have assessed the 
use of such therapy for the prevention or treatment of peptic 
ulcer disease. Previous systematic reviews and meta-analyses 
have reported varying efficacy for specific drugs, or drug classes, 
on certain peptic ulcer disease outcomes in particular clinical 
settings, often in patients treated with non-steroidal anti-
inflammatory drugs (NSAIDs). However, a comprehensive 
summary of the relative and absolute effects of different 
gastroprotectant drugs on different types of upper 
gastrointestinal outcomes, with or without NSAID use, and in the 
context both of prevention and treatment, has not been 
reported.
Added value of the study
This meta-analysis of more than 1200 trials included around 
200 000 participants and quantified the relative treatment 
effects of available gastroprotectants in the settings of ulcer 
prevention, ulcer healing, and treatment of acute upper 
gastrointestinal bleeding. The findings provide evidence for 
benefits of gastroprotectant therapy in all three clinical 
contexts, with PPIs showing consistent superiority to other 
agents. The relative benefits of gastroprotectants were of 
broadly similar magnitude irrespective of whether patients 
were taking NSAIDs. In the absence of large-scale randomised 
trials, however, some uncertainty remains about whether the 
effect size estimates in this meta-analysis were inflated by small 
study bias, and insufficient reliable information is available on 
the safety of such treatments.
Implications of all the available evidence
This study indicates that, in the context of peptic ulcer disease, 
gastroprotectants—and in particular PPIs—are effective in ulcer 
prevention, ulcer healing, and in reducing rebleeding. The 
relative benefits appear similar irrespective of concomitant 
NSAID use. Reliable information is still needed about the 
long-term safety of PPIs; in particular, there is concern that PPIs 
might have adverse cardiovascular effects. The large ongoing 
COMPASS trial of pantoprazole versus placebo in 
17 000 patients with stable cardiovascular disease might 
provide useful safety information, and could also help to 
determine the true size of any beneficial effects.
See Online for appendix
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prostaglandin analogue, or H2RA—and if they included a 
comparison of a gastroprotectant versus placebo or open 
control (no gastroprotectant; henceforth referred to as 
control), or a gastroprotectant of a given class versus a 
gastroprotectant of another class.
Review of the data indicated that the published trials 
had assessed gastroprotectant drugs in three main 
clinical scenarios: people with no ulcer at baseline 
(so-called prevention trials); people with a non-bleeding 
ulcer at baseline (so-called healing trials); and people 
presenting with upper gastrointestinal bleeding at 
baseline, with or without a confirmed diagnosis of peptic 
ulcer disease (so-called acute upper gastrointestinal 
bleeding treatment trials).
Data analyses
Two authors (two of HH, KD, KW, and LH) independently 
extracted key trial characteristics (including trial design, 
number of patients randomised, and indication) and 
prespecificed outcomes, with extracted information 
entered into a customised database. Where possible, a 
different pair of reviewers to those who extracted the data 
assessed the trial for inclusion. We used the trialists’ own 
definitions of outcomes as far as possible (appendix p 2). 
When definitions were inconsistent, events were 
adjudicated by at least two reviewers, including one 
clinician (NB or BS), until resolved. We recorded the 
number of patients who experienced each outcome; 
patients with multiple experiences of the same outcome 
were only counted once. However, where possible, 
outcome data were extracted for separate mucosal sites 
(gastric or duodenal). The mortality outcome included 
deaths recorded up to the end of each trial.
We did intention-to-treat analyses of the effects of 
gastroprotectant drugs overall, according to the class of 
gastroprotectant, and according to the individual drug 
within a gastroprotectant class. Only trials with at least 
one relevant event were included in analyses, and all 
statistical tests were two-sided. The main meta-analyses 
employed inverse-variance weighted methods for 
combining 2 × 2 contingency tables, as previously 
described.10 To allow for multiple subdivisions of the 
data, only summary odds ratios (ORs) are presented 
with 95% CIs; all other ORs are presented with 99% CIs. 
We calculated absolute effects from the crude differences 
between treatment groups.
We did exploratory analyses according to drug dose; 
NSAID use at randomisation; reported method of 
allocation concealment (sealed envelopes, closed list of 
random numbers, or unspecified method vs secure 
method) and method of blinding (double blind vs other). 
Additionally, we used a network meta-analysis approach 
to combine the direct and indirect randomised evidence 
(using the “netmeta” function in R). We created funnel 
plots to help to visually assess how the results from the 
larger trials (nearer the tip of each funnel) compared with 
the results from the smaller trials (nearer the base), with 
Egger’s statistics used to test for bias through funnel plot 
asymmetry.
We did all statistical analyses using SAS version 9.3 
and R for Windows version 3.2.4.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to the data and 
had final responsibility for the decision to submit for 
publication.
Results
We found 24 671 titles and abstracts from which we 
identified 1212 unconfounded randomised trials for 
analysis (see PRISMA11 diagram [figure 1]; details of 
included trials and their main design features are in the 
appendix, pp 37–91). Data from comparisons of a 
gastroprotectant versus control were available in 849 trials 
with a total of 142 485 participants (table). Endpoints of a 
8155 duplicates removed
22 035 excluded on the basis of title and abstract
24 671 identified for screening
1350 eligible articles, including
1212 eligible trials†
2636 full-text articles assessed for
eligibility
32 826 articles identified
10 260 through MEDLINE search
22 555 through Embase search
11 through manual search
1286 articles (including 1286 trials) excluded, plus 
  an additional 17 trials reported in articles 
  that also contained an eligible trial. 
  These 1303 trials were excluded for the 
  following primary reasons
  229 trials not randomised
     92 trials too short (<2 weeks for 
            prevention or healing trials)
  411 unsuitable or confounded comparison
  508 different-dose or within-class
   comparison
  20 trials of children (<18 years)
  13 trials in critical care settings
  10 review articles
  5 ongoing trials
  4 variceal indication
  11 articles unobtainable*
Figure 1: PRISMA diagram
*Full-text copies of these articles were unobtainable from all available sources 
including the British Library. †Some trials were published in more than one article 
(and, conversely, a few articles reported results from more than one trial).
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relevant type were reported for 55% of prevention trials, 
92% of healing trials, and 94% of acute upper 
gastrointestinal bleeding treatment trials (table). Data 
from comparisons of one gastroprotectant versus a 
gastroprotectant of a different class were available in 
345 trials (table). Endpoints of a relevant type were 
reported for 54% of prevention trials, 92% of healing 
trials, and 94% of acute bleeding trials (table). 11 trials 
had a comparison both of a gastroprotectant versus 
control and of one gastroprotectant versus another 
gastroprotectant. 29 trials did not report the number 
of participants randomised, and therefore were not 
included in analyses; this exclusion occurred after initial 
assessments of eligibility. The median number of 
participants in each trial was 78 (IQR 44·0–210·5): 
97 (IQR 50–278) in the prevention trials, 59 (36–121) in 
the healing trials, and 147 (70–289) in the acute upper 
gastrointestinal bleeding trials. The median duration of 
the trials was 1·4 months (IQR 0·9–2·8): 180 days 
(84–360) in the prevention trials, 30 days (28–42) in the 
healing trials and 3 days (2–4) in the acute upper 
gastrointestinal bleeding trials.
In prevention trials, we found that overall, compared 
with control, allocation to a gastroprotectant drug 
resulted in a substantial reduction in the odds of an 
endoscopic ulcer (OR 0·27 [95% CI 0·25–0·29]; absolute 
benefit 160 events [151–168] avoided per 1000 patients 
allocated treatment; p<0·0001). PPIs appeared to be 
more effective (OR 0·20 [99% CI 0·17–0·23]) than 
prostaglandin analogues (0·26 [0·20–0·32]) or H2RAs 
(0·32 [0·28–0·35]; phet<0·0001; figure 2). The relative 
effectiveness of particular gastroprotectant classes on 
duodenal ulcers and gastric ulcers also differed 
significantly: for trials of a gastroprotectant versus 
control in duodenal ulcer prevention, PPIs were the most 
effective gastroprotectant class, followed by H2RAs and 
finally prostaglandin analogues (figure 2), which was 
consistent with the ordering implied by the results of 
trials comparing one gastroprotectant class with another 
gastroprotectant class (appendix p 3). For prevention of 
gastric ulcers, however, the analogous ordering of 
effectiveness was prostaglandin analogues, followed by 
PPIs and finally H2RAs, and this was again consistent 
with the ordering implied by the results of trials directly 
comparing different gastroprotectant classes. PPIs were 
more effective at reducing the risk of duodenal ulcers 
than of gastric ulcers (p<0·0001; figure 2).
Few data were available with which to assess the 
relative efficacy of drugs within each gastroprotectant 
class, but the available trials provided no evidence that 
any individual PPI or prostaglandin analogue was more 
effective for the prevention of endoscopic ulcer than any 
other in the same class and we found little evidence of 
heterogeneity in treatment effects among H2RAs 
(phet=0·0286; appendix p 4).
Overall, compared with control, allocation to a 
gastroprotectant drug resulted in a substantial reduction in 
the odds of a symptomatic ulcer (OR 0·25 [95% CI 
0·22–0·29]; absolute benefit 67 [59–75] events avoided per 
1000 allocated treatment; p<0·0001; figure 2). However, 
because there were only about a third as many symptomatic 
ulcers as endoscopic ulcers available for analysis, the 
Prevention trials Healing trials Acute bleeding trials
Trials Participants Trials Participants Trials Participants
Gastroprotectant vs control
Endoscopic ulcer* 162 (28%) 31 580 (29%) 207 (89%) 22 086 (92%) ·· ··
Symptomatic ulcer* 73 (13%) 21 505 (19%) ·· ·· ·· ··
All-cause mortality 185 (32%) 57 472 (52%) 43 (18%) 6243 (26%) 31 (86%) 7596 (97%)
Further bleeding, endoscopy, surgery, or transfusion ·· ·· ·· ·· 33 (92%) 7662 (98%)
Bleeds, perforations, or obstructions 115 (20%) 41 764 (38%) ·· ·· ·· ··
No data available for any of the above outcomes 259 (45%) 33 122 (30%) 18 (8%) 1250 (5%) 2 (6%) 106 (1%)
Total 580 110 626 233 24 033 36 7826
Gastroprotectant vs a different class of gastroprotectant
Endoscopic ulcer* 22 (14%) 5781 (18%) 150 (90%) 25 494 (90%) ·· ··
Symptomatic ulcer* 15 (9%) 3199 (10%) ·· ·· ·· ··
All-cause mortality 61 (38%) 10 716 (33%) 68 (41%) 11 739 (41%) 16 (89%) 3478 (96%)
Further bleeding, endoscopy, surgery, or transfusion ·· ·· ·· ·· 17 (94%) 3518 (97%)
Bleeds, perforations, or obstructions 41 (26%) 8065 (24%) ·· ·· ·· ··
No data available for any of the above outcomes 74 (46%) 16 813 (51%) 14 (8%) 2661 (9%) 1 (6%) 122 (3%)
Total 160 32 959 167 28 306 18 3640
Trials in which an event is reported as not occurring (ie, 0 vs 0) are considered to have data available. In addition to the trials included in this table, there were 29 eligible trials 
for which the number of patients randomised was not available. No events were reported in any of these 29 trials. *Duodenal, gastric, or any reported ulcer.
Table: Availability of data for measuring the effects of gastroprotectants
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relative effectiveness of individual gastroprotectant classes 
on symptomatic ulcers was less clear. Overall, PPIs were 
more effective than were H2RAs and prostaglandin 
analogues (between the three classes phet=0·0018), but data 
were insufficient to provide separate estimates of 
effectiveness for duodenal and gastric ulcers (figure 2). We 
found no clear evidence that any individual PPI or 
prostaglandin analogue was more effective for the 
prevention of symptomatic ulcer than any other of the 
same class (appendix p 5), and only weak evidence of 
heterogeneity in treatment effects among H2RAs 
(phet=0·0447; appendix p 5).
Overall, compared with control, allocation to a 
gastroprotectant resulted in a substantial reduction in 
the odds of upper gastrointestinal bleeding (OR 0·40 
[95% CI 0·32–0·50], absolute benefit 12 [9–15] avoided 
per 1000 allocated treatment; p<0·0001; figure 3). The 
effects of PPIs on ulcer bleeding were similar after 
exclusion of data from the COGENT trial12 (all trials 
OR 0·21 [95% CI 0·14–0·32]; after excluding COGENT 
0·17 [0·10–0·28]). Larger proportional reductions in ulcer 
bleeding were observed for PPIs than for prostaglandin 
analogues or H2RAs (figure 3). We found no evidence that 
individual PPIs differed in their effects on bleeding 
(phet=0·48; appendix p 6). Ranitidine appeared more 
effective than other H2RAs for the prevention of ulcer 
bleeding (phet=0·0012; appendix p 6). Few data were 
available on perforations and obstructions, but overall, 
compared with control, allocation to a gastroprotectant 
resulted in a substantial reduction in the odds of 
Odds ratio
(95% or 99% CI)*
Number of
trials
Events/patients (%)
Gastroprotectant Control
29
22
105
152
22
17
81
116
19
19
39
74
8
4
39
51
1
1
29
31
0
2
6
8
0·20 (0·17−0·23)
0·26 (0·20−0·32)
0·32 (0·28−0·35)
0·27 (0·25−0·29; p<0·0001)
0·14 (0·10−0·19)
0·41 (0·28−0·61)
0·29 (0·26−0·34)
0·27 (0·25−0·30; p<0·0001)
0·26 (0·21−0·32)
0·22 (0·16−0·29)
0·39 (0·32−0·48)
0·30 (0·27−0·33; p<0·0001)
0·15 (0·09−0·23)
0·38 (0·18−0·79)
0·27 (0·23−0·32)
0·25 (0·22−0·29; p<0·0001)
0·05 (0·02−0·15)
0·52 (0·15−1·75)
0·26 (0·21−0·31)
0·25 (0·21−0·28; p<0·0001)
··
0·44 (0·14−1·38)
0·48 (0·28−0·83)
0·47 (0·32−0·69; p<0·0001)
314/6541 (5%)
228/3427 (7%)
1347/8074 (17%)
1889/18 042 (10%)
59/3846 (2%)
96/3187 (3%)
1008/6939 (15%)
1163/13 972 (8%)
212/4150 (5%)
127/3323 (4%)
327/3857 (8%)
666/11 330 (6%)
28/2585 (1%)
14/4619 (<1%)
481/2653 (18%)
523/9857 (5%)
1/60 (2%)
7/4404 (<1%)
404/2204 (18%)
412/6668 (6%)
··
7/4444 (<1%)
64/228 (28%)
71/4672 (2%)
937/4912 (19%)
435/2532 (17%)
2298/6187 (37%)
3502/13 255 (26%)
286/3042 (9%)
132/2324 (6%)
1709/5083 (34%)
2085/10 073 (21%)
501/3356 (15%)
310/2440 (13%)
572/2845 (20%)
1257/8277 (15%)
152/2587 (6%)
41/4673 (1%)
943/2184 (43%)
1136/9444 (12%)
44/63 (70%)
14/4439 (<1%)
786/1734 (45%)
844/6236 (14%)
··
17/4482 (<1%)
97/224 (43%)
114/4706 (2%)
Less likely with
gastroprotectant
 More likely with
gastroprotectant
0·50·1 20·25 1
Endoscopic ulcers
Any (heterogeneity χ²=39·5, p<0·0001)
   PPI
   Prostaglandin analogue
   H2RA
   Any gastroprotectant
Duodenal (heterogeneity χ²=39·0, p<0·0001)
   PPI
   Prostaglandin analogue
   H2RA
   Any gastroprotectant
Gastric (heterogeneity χ²=25·0, p<0·0001)
   PPI
   Prostaglandin analogue
   H2RA
   Any gastroprotectant
Symptomatic ulcers
Any (heterogeneity χ²=12·7, p=0·0018)
   PPI
   Prostaglandin analogue
   H2RA
   Any gastroprotectant
Duodenal (heterogeneity χ²=19·6, p<0·0001)
   PPI
   Prostaglandin analogue
   H2RA
   Any gastroprotectant
Gastric (heterogeneity χ²=0·0, p=0·85)
   PPI
   Prostaglandin analogue
   H2RA
   Any gastroprotectant
₂
₂
₂
₂
₂
₁
99% CI
95% CI
Figure 2: Prevention trials: effects of gastroprotectants on endoscopic and symptomatic ulcers
For 97 trials for the endoscopic outcome and 36 trials for the symptomatic outcome, in which the total number of ulcers was not reported but the breakdown was, 
we assumed that the total number of ulcers was equal to gastric plus duodenal: 1256 of 7414 events vs 2277 of 5766 events for endoscopic ulcers and 469 of 2492 events 
vs 927 of 2021 events for symptomatic ulcers. PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are 
presented with 95% CIs; all other odds ratios are presented with 99% CIs.
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gastrointestinal perforation (OR 0·21, 0·06–0·81; 
p=0·0089) and a non-significant reduction in the odds of 
gastrointestinal obstruction (0·43, 0·13–1·42; p=0·12; 
figure 3). Allocation to a gastroprotectant had no significant 
effect on all-cause mortality, either overall or for any 
individual gastroprotectant class (figure 3).
Overall, compared with control, the proportional effects 
of gastroprotectants on endoscopic ulcers, symptomatic 
ulcers, bleeds, and mortality were similar irrespective of 
NSAID use at the randomisation visit (all heterogeneity 
p values non-significant; figure 4). The results for trials in 
which information about NSAID use at baseline was 
unavailable were similar to those with data available: any 
endoscopic ulcer: OR 0·28 (99% CI 0·24–0·32) 
unavailable versus 0·27 (0·25–0·29) available; any 
sympto matic ulcer: 0·29 (0·23–0·36) versus 0·22 
(0·18–0·26); bleeds: 0·62 (0·33–1·14) versus 0·34 
(0·26–0·45); and all-cause mortality: 0·81 (0·60–1·10) 
versus 1·03 (0·64–1·65). PPIs were effective in prevention 
of endoscopic and symptomatic ulcers irrespective of the 
use of NSAIDs, although for endoscopic ulcers the 
proportional odds reduction appeared to be greater in 
those not taking NSAIDs at trial entry (appendix p 7).
For cimetidine, the proportional reduction in 
endoscopic ulcers in the prevention trials increased with 
dose studied (ptrend<0·0001). For the other three drugs, we 
found no evidence that their benefits increased with 
increasing dose (appendix p 8).
In the healing trials, we found that allocation to a 
gastroprotectant drug more than trebled the odds of 
endoscopic ulcer healing overall, compared with control 
(207 trials with median duration 0·9 months [IQR 
0·9–1·4]: OR 3·49 [95% CI 3·28–3·72]; absolute benefit 
261 [247–274] avoided per 1000 allocated treatment; 
p<0·0001; figure 5). Based on trials comparing a 
gastroprotectant with control, the order of effectiveness of 
gastroprotectant classes for duodenal and gastric ulcer 
healing was: PPIs as the most effective, followed by 
H2RAs and finally prostaglandin analogues (phet<0·0001 
and phet=0·0325 respectively; figure 5). This order was 
consistent with the ordering implied by the results of 
direct comparisons of one gastroprotectant class versus 
another gastroprotectant class (appendix p 9).
Individual PPIs were all effective for endoscopic ulcer 
healing, but differed in their degree of effect (phet=0·0010; 
appendix p 10), with lansoprazole and pantoprazole 
seemingly exhibiting the largest effects and esomeprazole 
the smallest. We found no significant differences 
between individual H2RAs or prostaglandin analogues 
(appendix p 10).
As was observed in the prevention trials (appendix p 8), 
we found some evidence that the proportional increase 
in endoscopic ulcer healing for cimetidine was greater at 
higher doses (ptrend=0·0478; appendix p 11).
In the trials for treatment of acute upper gastrointestinal 
bleeding, we found that, overall, allocation to a gastro-
Figure 3: Prevention trials: effects of gastroprotectants on ulcer complications and all-cause mortality
PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios 
are presented with 99% CIs.
Odds ratio
(95% or 99% CI)*
Number of
trials
Events/patients (%)
Gastroprotectant Control
18
3
29
49
3
2
1
5
1
1
2
4
18
4
29
51
0·21 (0·12−0·36)
0·63 (0·35−1·12)
0·49 (0·30−0·80)
0·40 (0·32−0·50; p<0·0001)
0·31 (0·01−13·74)
0·19 (0·03−1·37)
··
0·21 (0·06−0·81; p=0·0089)
··
0·14 (0·00−5·20)
0·52 (0·07−3·68)
0·43 (0·13−1·42; p=0·12)
1·01 (0·50−2·05)
0·81 (0·32−2·00)
0·83 (0·61−1·13)
0·85 (0·69−1·04; p=0·11)
14/5910 (<1%)
33/4464 (1%)
43/3631 (1%)
90/14 139 (1%)
1/1917 (<1%)
1/4700 (<1%)
0/49 (0%)
2/6666 (<1%)
1/1938 (<1%)
0/4404 (0%)
3/394 (1%)
4/6736 (<1%)
37/7471 (<1%)
17/4853 (<1%)
420/3520 (12%)
474/15 844 (3%)
88/4937 (2%)
53/4489 (1%)
84/2779 (3%)
221/12 130 (2%)
2/981 (<1%)
8/4594 (<1%)
1/50 (2%)
10/5470 (<1%)
1/1935 (<1%)
3/4439 (<1%)
6/404 (1%)
10/6778 (<1%)
31/5352 (1%)
20/4752 (<1%)
445/2959 (15%)
496/13 063 (4%)
Less likely with
gastroprotectant
 More likely with
gastroprotectant
0·50·1 2·51
Bleeds (heterogeneity χ²=15·3, p=0·0005)
   PPI
   Prostaglandin analogue
   H2RA
   Any gastroprotectant
Perforations (heterogeneity χ²=0·2, p=0·92)
   PPI
   Prostaglandin analogue
   H2RA
   Any gastroprotectant
Obstructions (heterogeneity χ²=1·4, p=0·49)
   PPI
   Prostaglandin analogue
   H2RA
   Any gastroprotectant
All-cause mortality (heterogeneity χ²=0·5, p=0·77)
   PPI
   Prostaglandin analogue
   H2RA
   Any gastroprotectant
₂
₂
₂
₂
99% CI
95% CI
Articles
www.thelancet.com/gastrohep   Vol 3   April 2018 237
protectant reduced the odds of further bleeding (30 trials 
with median duration of 3 days [IQR 2·00–4·00]: 
OR 0·68 [95% CI 0·60–0·78]; absolute benefit 49 [33–66] 
per 1000 allocated treatment; p<0·0001); blood transfusion 
(ten trials with median duration 2·5 days (2·00–3·75): 
OR 0·75 [0·65–0·88]; absolute benefit 67 [30–104] per 
1000 allocated treatment; p<0·0001); further endoscopic 
intervention (eight trials with median duration 3 days 
[2·50–3·00]: OR 0·56 [0·45–0·70], absolute benefit 
49 [30–68] per 1000 allocated treatment; p<0·0001); and 
Figure 4: Prevention trials: effects of gastroprotectants on endoscopic and symptomatic ulcers, bleeds, and all-cause mortality, subdivided by use of NSAIDs
We categorised trials by NSAID use, defining NSAID use as at least 80% of patients took a traditional NSAID, coxib, or aspirin, and no NSAID use as fewer than 80% of 
patients took a traditional NSAID, coxib, or aspirin. NSAID=non-steroidal anti-inflammatory drugs. *Summary odds ratios, indicated by diamonds, are presented with 
95% CIs; all other odds ratios are presented with 99% CIs.
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Figure 5: Healing trials: effects of gastroprotectants on ulcer healing
We counted the number of patients who became ulcer free on endoscopy post treatment. For 204 trials for the endoscopic outcome, the total number of ulcers was 
not reported but the breakdown was; we assumed that the total number of ulcers was equal to gastric plus duodenal: 8861 of 11 844 events vs 4040 of 8312 events. 
PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios 
are presented with 99% CIs.
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the need for surgery (27 trials with median duration 
3 days [2·00–3·50]: OR 0·72 [0·61–0·84]; absolute benefit 
31 [17–45] per 1000 allocated treatment; p<0·0001), but had 
no significant effect on all-cause mortality (figure 6).
PPIs were more effective than were H2RAs in prevention 
of further bleeding (phet=0·0107) and the need for blood 
transfusion (phet=0·0130; figure 6). The limited direct 
information available from head-to-head comparisons 
supported this suggestion of superiority of PPIs over 
H2RAs for further bleeds and also endoscopic 
interventions (appendix p 12), but not the need for 
transfusion (although only one small head-to-head trial 
assessed this outcome). The benefits of PPIs (but not other 
gastroprotectant classes) were larger in trials in which the 
cause of bleeding was definitely attributed to peptic ulcer 
(appendix p 13) than in trials in which the cause was 
uncertain (appendix p 14). We found no consistent 
evidence that any single PPI or H2RA was more effective 
for the treatment of acute upper gastrointestinal bleeding 
than any other of the same class (appendix pp 15–19).
When assessing the potential for bias, we found that 
the proportional reduction in symptomatic ulcers and 
bleeds was smaller in the trials known to have used a 
secure method of allocation concealment (phet<0·0001 
and phet=0·0002, respectively; appendix p 20); this was 
also the case, for bleeds only, in the trials that were 
double blind (phet=0·0006; appendix p 21). Among the 
analyses comparing a particular class of gastroprotectant 
versus control for various outcomes, no single trial 
dominated, and we found no consistent evidence of 
funnel plot asymmetry for any outcome in any of the 
three settings (prevention, healing, or acute upper 
gastrointestinal bleeding; appendix pp 22–24). The 
main results (arising from the direct head-to-head 
comparisons) were broadly similar to those derived 
from alternative network meta-analyses (appendix 
pp 25–33).
Discussion
This meta-analysis of data from more than 1200 randomised 
trials of the main gastroprotectant drugs currently in use, 
which included more than 200 000 participants in total, 
showed that gastroprotectant therapies are effective for the 
prevention and treatment of peptic ulcer disease and its 
main complication, upper gastrointestinal bleeding, in a 
wide range of clinical circumstances. However, the 
absence of individual trials that recorded large numbers 
of ulcer complications, and the paucity of reliable 
information on drug safety, are limitations that constrain 
wider use of such treatments.
The results of trials of a gastroprotectant versus control, 
and of one gastroprotectant versus another gastroprotectant 
of a different class, were consistent, with PPIs being more 
effective than other classes of gastroprotectant drugs; this 
Figure 6: Acute upper gastrointestinal bleeding treatment trials: effects of gastroprotectants on further bleeding, need for blood transfusion, endoscopic 
interventions, surgery, and all-cause mortality
PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios 
are presented with 99% CIs.
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superiority was observed uniformly in the separate clinical 
circumstances in which these agents are used in peptic 
ulcer disease, namely prevention, healing, and treatment 
of acute upper gastrointestinal bleeding. In the context of 
prevention, most information was available from trials 
assessing the effects of gastroprotectant drugs on endo-
scopic ulcers, but the evidence of benefit was corroborated 
by similar findings in the smaller number of trials 
assessing their effects on symptomatic ulcers. The relative 
benefits of gastroprotectants for the prevention of 
endoscopic ulcers, symptomatic ulcers, and bleeding were 
large and of broadly similar magnitude irrespective of 
whether patients were taking an NSAID (including 
aspirin). This result is especially relevant in view of the 
recent evidence of large excess risks of bleeding in 
association with aspirin use in the elderly,13 and hence the 
potential for wider use of gastroprotectant therapy 
(eg, PPIs) in this demographic group. Although the 
absolute risk of developing endoscopic or symptomatic 
ulcers was actually higher in trials with no concomitant 
NSAID use than in trials with NSAID use (figure 4; 
appendix p 7), this is probably due to the fact that many 
patients classed as not using NSAIDs in these trials had a 
history of a recently healed ulcer (and hence would be 
likely to be at higher risk of recurrence of further such 
events). We found some evidence to suggest that PPIs 
reduced the risk of duodenal ulcers more than gastric 
ulcers; however, the relevance of this result is uncertain. 
There was also a suggestion that prostaglandin analogues 
are at least as effective as PPIs for the prevention of gastric 
ulcers; however, the difference between drug classes was 
not as marked as for duodenal ulcers, and prostaglandin 
analogues are less well tolerated than PPIs because they 
cause nausea, diarrhoea, and abdominal pain, as previously 
highlighted by a Cochrane review on misoprostol.6
This meta-analysis confirmed that gastroprotectant 
therapies prevent the clinical symptoms of ulcers and 
reduce the risk of upper gastrointestinal bleeding. The 
COGENT trial12 previously found that the addition of 
omeprazole to dual antiplatelet therapy (clopidogrel plus 
aspirin) reduced the risk of upper gastrointestinal 
bleeding.14,15 Our meta-analysis suggests that this is a 
class-wide effect of PPIs and not restricted to omeprazole. 
A sensitivity analysis excluding the COGENT trial12 
data found a similar, slightly greater, reduction in 
bleeding risk.
This meta-analysis does not provide much information 
about the effects of gastroprotectant regimens on peptic 
ulcer disease complications other than bleeding; 
although our analyses suggested that gastroprotectant 
regimens might reduce the risk of perforation associated 
with peptic ulcer disease, perforations were reported in 
only five of 115 prevention trials that reported at least one 
complication. Although this small number of reports 
might be partly due to the brevity of follow-up and the 
rarity of this complication, it is possible that reporting of 
the results was biased in favour of trials reporting 
favourable findings. A similar limitation applies to 
gastric outlet obstruction, which was reported in just 
four prevention trials. Therefore, further randomised 
trial evidence is needed to determine the effects of 
gastroprotectant regimens on such complications. This 
meta-analysis showed that gastroprotectants effectively 
reduced the risk of further bleeding, the need for blood 
transfusion, and the need for further endoscopic 
intervention or surgery in upper gastrointestinal bleeding 
secondary to peptic ulcer disease. An exploratory analysis 
showed that gastroprotectants were less effective in 
acute bleeding trials that recruited patients with upper 
gastrointestinal bleeding of any cause and initiated 
treatment prior to endoscopic diagnosis. This result 
is qualitatively consistent with a previous Cochrane 
review16 that found no evidence that PPI treatment 
initiated before endoscopy for upper gastrointestinal 
bleeding significantly reduced mortality, rebleeding, or 
the need for surgery.
The major strengths of this meta-analysis are the large 
number of events overall, which allowed precise 
quantitative estimates of treatment effects, together with 
the diversity of inclusion criteria among the large 
number of trials, which allowed study of a wide range of 
patients at risk of peptic ulcer disease. However, the 
study has a number of limitations. By far the 
most important of these is the absence of large 
placebo-controlled randomised trials that individually 
recorded substantial numbers of upper gastrointestinal 
complications: almost all of the available trials were short 
term and included small numbers of bleeds, and 
furthermore many did not publish all relevant outcomes. 
Additionally, the decision to report particular findings in 
any given trial might have been determined post hoc by 
their statistical significance alone, which could inflate 
estimates of efficacy. This possibility is reinforced by 
the implausibly large effect sizes observed for some of 
the treatments and outcomes in our meta-analysis. Even 
though analysis of funnel plots in this meta-analysis did 
not provide consistent evidence of publication bias, such 
plots are known to be insensitive, and it is possible that 
small study bias17,18 might have led to overestimation of 
the magnitude of the relative and absolute benefits.
Second, although the results of trials comparing a 
gastroprotectant versus control and of trials comparing 
different classes of gastroprotectant yielded broadly 
consistent results on the relative effectiveness of 
PPIs, H2RAs, and prostaglandin analogues, and our 
exploratory network meta-analytic findings were 
generally (although not always) compatible with our 
primary effect estimates from trials of a gastroprotectant 
versus control, in the absence of individual participant 
data we were unable to check the assumptions underlying 
network meta-analysis (hence the decision to reserve 
the latter method for an exploratory analysis). Therefore, 
our estimates of the relative efficacy of different gastro-
protectants might be unreliable. Additionally, the absence 
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of individual participant data also meant that we were 
unable to explore potential modifiers of treatment 
effects or to investigate whether treatment effects varied 
over time.
Third, we were unable to explore the role of H pylori 
in this meta-analysis because of the inconsistency of 
recording of participant H pylori status; notably, many of 
the included trials pre-date the discovery of this pathogen. 
Similarly, although we assessed the effect of concomitant 
NSAID therapy on the effect of gastroprotectants in 
peptic ulcer disease, we could not assess whether other 
antithrombotic drugs (eg, vitamin K antagonists or novel 
oral anticoagulants) influenced the efficacy of gastro-
protectant therapy owing to inconsistent information on 
such drug use.
Fourth, we excluded studies in the critical care setting 
because this clinical scenario is often not considered to 
represent typical peptic ulcer disease, so the results of 
this meta-analysis cannot be generalised to prevention of 
bleeding from stress-related mucosal disease in this 
context. However, a systematic review and meta-analysis 
of critically ill patients has also reported PPIs as being 
superior to H2RAs in this setting.19 Interventional 
radiology is also now commonly used after failed 
endoscopy, but this approach was introduced after the 
completion of most of the trials in our meta-analysis.
Finally, our literature search, although exhaustive, was 
completed several years ago and is now out of date. 
However, an updated search to Nov 24, 2017, did not yield 
any large trials that, had they been included, would have 
materially altered our conclusions.
Although this meta-analysis provides strong evidence 
of efficacy for the prevention of upper gastrointestinal 
complications, the use of gastroprotectant therapy to 
reduce bleeding risk among patients at high risk of 
cardiovascular disease is limited by concerns about drug 
safety, especially if gastroprotectant drugs need to be 
taken long term. In particular, in observational studies, 
PPIs have been shown to be associated with an increased 
risk of myocardial infarction,20,21 bone fractures,22,23 
hypomagnesaemia,24,25 food poisoning and bacterial gut 
infections,26 dementia,27 and chronic kidney disease.28,29 
Despite the fact that the COGENT trial12 reported no 
apparent cardiovascular hazard of omeprazole, concerns 
about the cardiovascular safety of PPIs have persisted. 
In 2018, results are expected from a sub-study of the 
COMPASS trial (NCT01776424) comparing around 
3 years of pantoprazole versus placebo in 17 000 patients 
with stable cardiovascular disease who were treated with 
aspirin, rivaroxaban, or both drugs.30 Not only will this 
trial provide much needed information about long-term 
drug safety, but it will also help to determine the 
magnitude of any beneficial effects of a PPI more reliably 
than was possible in this meta-analysis.
In conclusion, this meta-analysis of randomised trials 
summarises the effects of gastroprotectant treatments 
on a range of outcomes in different treatment settings. 
PPIs generally appeared to be the most effective class of 
gastroprotectant for the management of peptic ulcer 
disease. Gastroprotectant drugs, many of which are 
available cheaply in generic form, are a potential 
strategy for reducing the global burden of peptic ulcer 
disease and, indirectly, might also have a beneficial 
effect on cardiovascular disease by allowing wider use 
of more potent antithrombotic regimens in high-risk 
patients.
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